FOXP3 facilitates the invasion and metastasis of non‑small cell lung cancer cells through regulating VEGF, EMT and the Notch1/Hes1 pathway

Li,Chun; Wang,Hefei; Fang,Hui; He,Chengyuan; Pei,Yijie; Gai,Xiaodong

doi:10.3892/etm.2021.10390

FOXP3 facilitates the invasion and metastasis of non‑small cell lung cancer cells through regulating VEGF, EMT and the Notch1/Hes1 pathway

Authors:
- Chun Li
- Hefei Wang
- Hui Fang
- Chengyuan He
- Yijie Pei
- Xiaodong Gai
View Affiliations

Affiliations: Department of Immunology, School of Basic Medical Sciences, Beihua University, Jilin, Jilin 132013, P.R. China, Department of Gynecology, The Third Affiliated Hospital of Xiang Ya School of Medicine, Central South University, Changsha, Hunan 410013, P.R. China
Published online on: July 6, 2021 https://doi.org/10.3892/etm.2021.10390
Article Number: 958
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Forkhead box P3 (FOXP3) is a specific marker of regulatory T cells (Tregs) that is also expressed in tumour cells. Previous studies have revealed that FOXP3 can promote metastasis in several types of cancer, including non‑small cell lung cancer (NSCLC); however, the underlying mechanism of FOXP3 remains unclear. The aim of the present study was to investigate the effect of FOXP3 on vascular endothelial growth factor (VEGF), epithelial‑to‑mesenchymal transition (EMT) and the Notch1/Hes1 pathway in NSCLC. After FOXP3 small interfering RNA (siRNAs) were transfected into A549 cells, the expression of FOXP3 mRNA and protein was determined by reverse transcription‑quantitative PCR and western blotting. Cell migration and invasion were analyzed by Transwell assays. The concentrations of matrix metalloproteinase (MMP)‑2, MMP‑9 and VEGF in the cell supernatant were evaluated by ELISA. The expression of relevant proteins involved in EMT and Notch1/Hes1 pathway were assessed via western blotting. Additionally, the expression of FOXP3, CD31 and E‑cadherin was detected by immunohistochemical (IHC) staining of 55 human NSCLC tissue samples. The results demonstrated that FOXP3 knockdown significantly inhibited the cell migratory and invasive abilities, decreased the concentrations of MMP‑2, MMP‑9 and VEGF, downregulated the protein expression of vimentin, N‑cadherin, Notch1 and Hes family BHLH transcription factor 1 (Hes1), and upregulated the protein expression of E‑cadherin. Furthermore, FOXP3 expression was positively associated with CD31⁺ vascular endothelial cells and negatively correlated with E‑cadherin in NSCLC tissues. In addition, the Notch1/Hes1 pathway inhibitor DAPT significantly downregulated the expression of FOXP3 in a dose‑dependent manner. Taken together, these findings demonstrated that FOXP3 may facilitate the invasive and migratory abilities of NSCLC cells via regulating the angiogenic factor VEGF, the EMT and the Notch1/Hes1 pathway.

View Figures

View References

1	Torre LA, Siegel RL and Jemal A: Lung cancer statistics. Adv Exp Med Biol. 893:1–19. 2016.PubMed/NCBI View Article : Google Scholar
2	Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current therapies and new targeted treatments. Lancet. 389:299–311. 2017.PubMed/NCBI View Article : Google Scholar
3	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.PubMed/NCBI View Article : Google Scholar
4	Souza MC, Cruz OG and Vasconcelos AG: Factors Associated with disease-specific survival of patients with non-small cell lung cancer. J Bras Pneumol. 42:317–325. 2016.PubMed/NCBI View Article : Google Scholar : (In English, Portuguese).
5	Zinner R, Visseren-Grul C, Spigel DR and Obasaju C: Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review). Int J Oncol. 48:13–27. 2016.PubMed/NCBI View Article : Google Scholar
6	Togashi Y, Shitara K and Nishikawa H: Regulatory T cells in cancer immunosuppression-implications for anticancer therapy. Nat Rev Clin Oncol. 16:356–371. 2019.PubMed/NCBI View Article : Google Scholar
7	Triulzi T, Tagliabue E, Balsari A and Casalini P: FOXP3 expression in tumor cells and implications for cancer progression. J Cell Physiol. 228:30–35. 2013.PubMed/NCBI View Article : Google Scholar
8	Hinz S, Pagerols-Raluy L, Oberg HH, Ammerpohl O, Grüssel S, Sipos B, Grützmann R, Pilarsky C, Ungefroren H, Saeger HD, et al: Foxp3 expression in pancreatic carcinoma cells as a noveral mechanism of immune evasion in cancer. Cancer Res. 67:8344–8350. 2007.PubMed/NCBI View Article : Google Scholar
9	Kim M, Grimmig T, Grimm M, Lazariotou M, Meier E, Rosenwald A, Tsaur I, Blaheta R, Heemann U, Germer CT, et al: Expression of Foxp3 in colorectal cancer but not in Treg cells correlates with disease progression in patients with colorectal cancer. PLoS One. 8(e53630)2013.PubMed/NCBI View Article : Google Scholar
10	Chu R, Liu SY, Vlantis AC, van Hasselt CA, Ng EK, Fan MD, Ng SK, Chan AB, Du J, Wei W, et al: Inhibition of Foxp3 in cancer cells induces apoptosis of thyroid cancer cells. Mol Cell Endocrinol. 399:228–234. 2015.PubMed/NCBI View Article : Google Scholar
11	Zeng C, Yao Y, Jie W, Zhang M, Hu X, Zhao Y, Wang S, Yin J and Song Y: Up-regulation of Foxp3 participates in progression of cervical cancer. Cancer Immunol Immunother. 62:481–487. 2013.PubMed/NCBI View Article : Google Scholar
12	Zuo T, Wang L, Morrison C, Chang X, Zhang H, Li W, Liu Y, Wang Y, Liu X, Chan MW, et al: FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell. 129:1275–1286. 2007.PubMed/NCBI View Article : Google Scholar
13	Wang L, Liu R, Li W, Chen C, Katoh H, Chen GY, McNally B, Lin L, Zhou P, Zuo T, et al: Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell. 16:336–346. 2009.PubMed/NCBI View Article : Google Scholar
14	Zhang HY and Sun H: Up-regulation of Foxp3 inhibits cell proliferation, migration and invasion in epithelial ovarian cancer. Cancer Lett. 287:91–97. 2010.PubMed/NCBI View Article : Google Scholar
15	Luo X, Tan H, Zhou Y, Xiao T, Wang C and Li Y: Notch1 signaling is involved in regulating Foxp3 expression in T-ALL. Cancer Cell Int. 13(34)2013.PubMed/NCBI View Article : Google Scholar
16	Fu HY, Li C, Yang W, Gai XD, Jia T, Lei YM and Li Y: FOXP3 and TLR4 protein expression are correlated in non-small cell lung cancer: Implications for tumor progression and escape. Acta Histochem. 115:151–157. 2013.PubMed/NCBI View Article : Google Scholar
17	Li C, Sun L, Jiang R, Wang P, Xue H, Zhan Y and Gai X: Downregulation of FOXP3 inhibits cell proliferation and enhances chemosensitivity to cisplatin in human lung adenocarcinoma. Pathol Res Pract. 213:1251–1256. 2017.PubMed/NCBI View Article : Google Scholar
18	Li C, Yang W, Gai X, Zhang Y, Li Y and Fu H: Foxp3 overexpression decreases sensitivity to chemotherapy in mouse Lewis lung cancer cells. Mol Med Rep. 6:977–982. 2012.PubMed/NCBI View Article : Google Scholar
19	Li Y, Li D, Yang W, Fu H, Liu Y and Li Y: Overexpression of the transcription factor FOXP3 in lung adenocarcinoma sustains malignant character by promoting G1/S transition gene CCND1. Tumour Biol. 37:7395–7404. 2016.PubMed/NCBI View Article : Google Scholar
20	Yang S, Liu Y, Li MY, Ng CSH, Yang SL, Wang S, Zou C, Dong Y, Du J, Long X, et al: FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancer. Mol Cancer. 16(124)2017.PubMed/NCBI View Article : Google Scholar
21	Valastyan S and Weinberg RA: Tumor metastasis: Molecular insights and evolving paradigms. Cell. 147:275–292. 2011.PubMed/NCBI View Article : Google Scholar
22	Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, Yang SX and Ivy SP: Targeting notch Hedgehog, and Wnt pathways in cancer stem cells: Clinical update. Nat Rev Clin Oncol. 12:445–464. 2015.PubMed/NCBI View Article : Google Scholar
23	Yang Z, Qi Y, Lai N, Zhang J, Chen Z, Liu M, Zhang W, Luo R and Kang S: Notch1 signaling in melanoma cells promoted tumor-induced immunosuppression via upregulation of TGF-β1. J Exp Clin Cancer Res. 37(1)2018.PubMed/NCBI View Article : Google Scholar
24	Teoh SL and Das S: Notch signalling pathways and their importance in the treatment of cancers. Curr Drug Targets. 19:128–143. 2018.PubMed/NCBI View Article : Google Scholar
25	Zou B, Zhou XL, Lai SQ and Liu JC: Notch signaling and non-small cell lung cancer. Oncol Lett. 15:3415–3421. 2018.PubMed/NCBI View Article : Google Scholar
26	Yuan X, Wu H, Xu H, Han N, Chu Q, Yu S, Chen Y and Wu K: Meta-analysis reveals the correlation of Notch signaling with non-small cell lung cancer progression and prognosis. Sci Rep. 5(10338)2015.PubMed/NCBI View Article : Google Scholar
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta DeltaC (T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
28	Li C, Ma X, Tan C, Fang H, Sun Y and Gai X: IL-17F expression correlates with clinicopathologic factors and biological markers in non-small cell lung cancer. Pathol Res Pract. 215(152562)2019.PubMed/NCBI View Article : Google Scholar
29	Tang YQ, Jaganath IB, Manikam R and Sekaran SD: Phyllanthus spp. exerts anti-angiogenic and anti-metastatic effects through inhibition on matrix metalloproteinase enzymes. Nutr Cancer. 67:783–795. 2015.PubMed/NCBI View Article : Google Scholar
30	Pittayapruek P, Meephansan J, Prapapan O, Komine M and Ohtsuki M: Role of matrix metalloproteinases in photoaging and photocarcinogenesis. Int J Mol Sci. 17(868)2016.PubMed/NCBI View Article : Google Scholar
31	Zhao L, Niu H, Liu Y, Wang L, Zhang N, Zhang G, Liu R and Han M: LOX inhibition downregulates MMP-2 and MMP-9 in gastric cancer tissues and cells. J Cancer. 10:6481–6490. 2019.PubMed/NCBI View Article : Google Scholar
32	Giatromanolaki A, Lyberakidis G, Lyratzopoulos N, Koukourakis MI, Sivridis E and Manolas C: Angiogenesis and angiogenic factor expression in thyroid cancer. J BUON. 15:357–361. 2010.PubMed/NCBI
33	Sadremomtaz A, Kobarfard F, Mansouri K, Mirzanejad L and Asghari SM: Suppression of migratory and metastatic pathways via blocking VEGFR1 and VEGFR2. J Recept Signal Transduct Res. 38:432–441. 2018.PubMed/NCBI View Article : Google Scholar
34	Tang J, Yang Z, Wang Z, Li Z, Li H, Yin J, Deng M, Zhu W and Zeng C: Foxp3 is correlated with VEGF-C expression and lymphangiogenesis in cervical cancer. World J Surg Oncol. 15(173)2017.PubMed/NCBI View Article : Google Scholar
35	Li X, Gao Y, Li J, Zhang K, Han J, Li W, Hao Q, Zhang W, Wang S, Zeng C, et al: FOXP3 inhibits angiogenesis by downregulating VEGF in breast cancer. Cell Death Dis. 9(744)2018.PubMed/NCBI View Article : Google Scholar
36	Tsubakihara Y and Moustakas A: Epithelial-mesenchymal transition and metastasis under the control of transforming growth factor beta. Int J Mol Sci. 19(3672)2018.PubMed/NCBI View Article : Google Scholar
37	Li P, Sun T, Yuan Q, Pan G, Zhang J and Sun D: The expressions of NEDD9 and E-cadherin correlate with metastasis and poor prognosis in triple-negative breast cancer patients. Onco Targets Ther. 9:5751–5759. 2016.PubMed/NCBI View Article : Google Scholar
38	He X, Chen Z, Jia M and Zhao X: Downregulated E-cadherin expression indicates worse prognosis in Asian patients with colorectal cancer: Evidence from meta-analysis. PLoS One. 8(e70858)2013.PubMed/NCBI View Article : Google Scholar
39	Ancel J, Dewolf M, Deslée G, Nawrocky-Raby B, Dalstein V, Gilles C and Polette M: Clinical impact of the epithelial-mesenchymal transition in lung cancer as a biomarker assisting in therapeutic decisions. Cells Tissues Organs. 1–19. 2020.PubMed/NCBI View Article : Google Scholar : (Epub ahead of print).
40	Yang MH, Zang YS, Huang H, Chen K, Li B, Sun GY and Zhao XW: Arsenic trioxide exerts anti-lung cancer activity by inhibiting angiogenesis. Curr Cancer Drug Targets. 14:557–566. 2014.PubMed/NCBI View Article : Google Scholar
41	Gao YP, Li Y, Li HJ and Zhao B: LncRNA NBR2 inhibits EMT progression by regulating Notch1 pathway in NSCLC. Eur Rev Med Pharmacol Sci. 23:7950–7958. 2019.PubMed/NCBI View Article : Google Scholar
42	Skarmoutsou E, Bevelacqua V, D' Amico F, Russo A, Spandidos DA, Scalisi A, Malaponte G and Guarneri C: FOXP3 expression is modulated by TGF-β1/NOTCH1 pathway in human melanoma. Int J Mol Med. 42:392–404. 2018.PubMed/NCBI View Article : Google Scholar